Tirelizumab is effective in the treatment of lung adenocarcinoma. Tirelizumab is a kind of humanized monoclonal antibody, which plays an anti-tumor role by inhibiting T cell proliferation and cytokine production. It can be used in cancer diseases such as classic Hodgkin’s lymphoma, urothelial carcinoma, non-small cell lung cancer, hepatocellular carcinoma and so on. Lung adenocarcinoma is a type of lung cancer, which belongs to non-small cell carcinoma. It usually occurs in the glands of bronchial tubes or bronchial epithelium and manifests as dry cough, chest pain, and other symptoms. Tirilizumab can effectively relieve the adverse symptoms occurring in patients with lung adenocarcinoma. Tirelizumab may cause respiratory tract infection, urinary tract infection, cardiac arrhythmia and other adverse reactions during the medication, it is not recommended for patients with moderate or severe hepatic insufficiency, and patients with mild hepatic insufficiency should use it with caution under the guidance of doctor. It is contraindicated for those who are allergic to the ingredients of the drug. The drug should be used under the guidance of a doctor, do not blindly use the drug, so as not to delay the condition.